Form 4: Terns Pharmaceuticals Director Jill M. Quigley Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Jill M. Quigley exercised stock options and sold shares of Terns Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 9, 2024, Jill M. Quigley, a director of Terns Pharmaceuticals, exercised stock options to acquire 17,235 shares of common stock at a price of $1.82 per share.
• Simultaneously, Quigley sold 17,235 shares at $10 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 18, 2024.
• Following these transactions, Quigley directly owns 15,000 shares of Terns Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The execution of a 10b5-1 plan allows insiders to diversify their holdings while avoiding accusations of trading on inside information.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future stock performance.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares without raising concerns about insider trading.
• The reported transactions are typical for directors and officers who receive stock options as part of their compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they involve the sale of shares by a director.
• The impact is likely to be minimal due to the relatively small number of shares involved and the fact that the transactions were pre-planned.

Key Dates